Connect with us

Health & Fitness

Adjuvant Nivolumab: A New Standard of Care in High-risk MIUC?

Nivolumab is efficacious and well tolerated when used as adjuvant therapy in patients who have undergone radical surgery for high-risk, muscle-invasive urothelial carcinoma, new research suggests. Medscape Medical News

Published

on

Adjuvant Nivolumab: A New Standard of Care in High-risk MIUC?

Nivolumab is efficacious and well tolerated when used as adjuvant therapy in patients who have undergone radical surgery for high-risk, muscle-invasive urothelial carcinoma, new research suggests. Medscape Medical News
Read More